Clinicopathological significance of TM4SF5 expression in human hepatocellular carcinoma tissues

  • Authors:
    • Baojin Xu
    • Wu Lv
    • Xiaoyan Li
    • Lina Zhang
    • Jie Lin
  • View Affiliations

  • Published online on: April 3, 2019     https://doi.org/10.3892/ol.2019.10210
  • Pages: 5187-5192
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Hepatocellular carcinoma (HCC) is a major cause of cancer‑related mortality. Recent studies have indicated that transmembrane 4 L six family member 5 (TM4SF5) serves a vital role in tumor progression and metastasis in human cell lines and mouse models. However, little is known about the association between TM4SF5 expression and clinicopathological factors. The aim of the current study was to investigate this association and evaluate overall survival (OS) of patients. Immunohistochemistry and clinical record analysis revealed that TM4SF5 expression was significantly downregulated in HCC tissues. In addition, TM4SF5 expression was significantly associated with tumor size, vascular invasion, tumor differentiation, and tumor‑node‑metastasis stage. The survival analysis also demonstrated that low TM4SF5 expression resulted in shorter OS. In conclusion, the association between TM4SF5 expression and clinicopathologic factors was established, and prognostic significance of TM4SF5 as a potential biomarker was evaluated using human HCC formalin‑fixed paraffin‑embedded tissue samples. The results of the present study demonstrated that low TM4SF5 expression was associated with tumor malignant progression and may be a good prognostic biomarker for OS in HCC.

References

1 

Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI

2 

Tummala KS, Gomes AL, Yilmaz M, Graña O, Bakiri L, Ruppen I, Ximénez-Embún P, Sheshappanavar V, Rodriguez-Justo M, Pisano DG, et al: Inhibition of de novo NAD(+) synthesis by oncogenic URI causes liver tumorigenesis through DNA damage. Cancer Cell. 26:826–839. 2014. View Article : Google Scholar : PubMed/NCBI

3 

Lee SA, Park KH and Lee JW: Modulation of signaling between TM4SF5 and integrins in tumor microenvironment. Front Biosci (Landmark Ed). 16:1752–1758. 2011. View Article : Google Scholar : PubMed/NCBI

4 

Wright MD, Ni J and Rudy GB: The L6 membrane proteins-a new four-transmembrane superfamily. Protein Sci. 9:1594–1600. 2009. View Article : Google Scholar

5 

Lee SA, Ryu HW, Kim YM, Choi S, Lee MJ, Kwak TK, Kim HJ, Cho M, Park KH and Lee JW: Blockade of four-transmembrane L6 family member 5 (TM4SF5)-mediated tumorigenicity in hepatocytes by a synthetic chalcone derivative. Hepatology. 49:1316–1325. 2009. View Article : Google Scholar : PubMed/NCBI

6 

Wu YB, Huang YS, Xu YP, Sun YF, Yu DL, Zhang XQ, Long X, Zhu SQ, Zhou JL and Xu JJ: A high level of TM4SF5 is associated with human esophageal cancer progression and poor patient survival. Dig Dis Sci. 58:2623–2633. 2013. View Article : Google Scholar : PubMed/NCBI

7 

Park BK, Park JY, Kim TH, Kim D, Wu G, Gautam A, Maharjan S, Lee SI, Lee Y, Kwon HJ and Choi KC: Production of an anti-TM4SF5 monoclonal antibody and its application in the detection of TM4SF5 as a possible marker of a poor prognosis in colorectal cancer. Int J Oncol. 53:275–285. 2018.PubMed/NCBI

8 

Lee D and Lee JW: Self-renewal and circulating capacities of metastatic hepatocarcinoma cells required for collaboration between TM4SF5 and CD44. BMB Rep. 48:127–128. 2015. View Article : Google Scholar : PubMed/NCBI

9 

Amicone L and Marchetti A: Microenvironment and tumor cells: Two targets for new molecular therapies of hepatocellular carcinoma. Transl Gastroenterol Hepatol. 3:242018. View Article : Google Scholar : PubMed/NCBI

10 

Dutta R and Mahato RI: Recent advances in hepatocellular carcinoma therapy. Pharmacol Ther. 173:106–117. 2017. View Article : Google Scholar : PubMed/NCBI

11 

Reeves HL, Zaki MY and Day CP: Hepatocellular carcinoma in obesity, type 2 diabetes, and NAFLD. Dig Dis Sci. 61:1234–1245. 2016. View Article : Google Scholar : PubMed/NCBI

12 

Trojan J, Zangos S and Schnitzbauer AA: Diagnositics and treatment of hepatocellular carcinoma in 2016: Standrads and developments. Visc Med. 32:116–120. 2016. View Article : Google Scholar : PubMed/NCBI

13 

Lee SA, Lee SY, Cho IH, Oh MA, Kang ES, Kim YB, Seo WD, Choi S, Nam JO, Tamamori-Adachi M, et al: Tetraspanin TM4SF5 mediates loss of contact inhibition through epithelial- mesenchymal transition in human hepatocarcinoma. J Clin Invest. 118:1354–1366. 2008. View Article : Google Scholar : PubMed/NCBI

14 

Besson A, Gurian-West M, Schmidt A, Hall A and Roberts JM: p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev. 18:862–876. 2004. View Article : Google Scholar : PubMed/NCBI

15 

Kim H, Kang M, Lee SA, Kwak TK, Jung O, Lee HJ, Kim SH and Lee JW: TM4SF5 accelerates G1/S phase progression via cytosolic p27Kip1 expression and RhoA activity. Biochim Biophys Acta. 1803:975–982. 2010. View Article : Google Scholar : PubMed/NCBI

16 

Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI

17 

Sadej R, Romanska H, Baldwin G, Gkirtzimanaki K, Novitskaya V, Filer AD, Krcova Z, Kusinska R, Ehrmann J, Buckley CD, et al: CD151 regulates tumorigenesis by modulating the communication between tumor cells and endothelium. Mol Cancer Res. 7:787–798. 2009. View Article : Google Scholar : PubMed/NCBI

18 

Choi S, Lee S-A, Kwak TK, Kim HJ, Lee MJ, Ye SK, Kim SH, Kim S and Lee JW: Cooperation between integrin alpha5 and teraspan TM4SF5 regulates VEGF-mediated angiogenic activity. Blood. 113:1845–1855. 2009. View Article : Google Scholar : PubMed/NCBI

19 

Lee D, Na J, Ryu J, Kim HJ, Nam SH, Kang M, Jung JW, Lee MS, Song HE, Choi J, et al: Interaction of tetraspan(in) TM4SF5 with CD44 promotes self-renewal and circulating capacities of hepatocarcinoma cells. Hepatology. 61:1978–1997. 2015. View Article : Google Scholar : PubMed/NCBI

20 

Kim H, Jung O, Kang M, Lee MS, Jeong D, Ryu J, Ko Y, Choi YJ and Lee JW: JNK signaling activity regulates cell-cell adhesions via TM4SF5-mediated p27(Kip1) phosphorylation. Cancer Lett. 314:198–205. 2012. View Article : Google Scholar : PubMed/NCBI

21 

Ryu J, Kang M, Lee MS, Kim HJ, Nam SH, Song HE, Lee D and Lee JW: Cross talk between the TM4SF5/focal adhesion kinase and the interleukin-6/STAT3 pathways promotes immune escape of human liver cancer cells. Mol Cell Biol. 34:2946–2960. 2014. View Article : Google Scholar : PubMed/NCBI

22 

Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Xu, B., Lv, W., Li, X., Zhang, L., & Lin, J. (2019). Clinicopathological significance of TM4SF5 expression in human hepatocellular carcinoma tissues. Oncology Letters, 17, 5187-5192. https://doi.org/10.3892/ol.2019.10210
MLA
Xu, B., Lv, W., Li, X., Zhang, L., Lin, J."Clinicopathological significance of TM4SF5 expression in human hepatocellular carcinoma tissues". Oncology Letters 17.6 (2019): 5187-5192.
Chicago
Xu, B., Lv, W., Li, X., Zhang, L., Lin, J."Clinicopathological significance of TM4SF5 expression in human hepatocellular carcinoma tissues". Oncology Letters 17, no. 6 (2019): 5187-5192. https://doi.org/10.3892/ol.2019.10210